Patient & Visitor Alert: Because flu cases are on the rise, starting February 24, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities throughout Carolinas HealthCare System. Learn more.
The research study involves an investigational drug called tirasemtiv which is being investigated as a potential new therapy for the improvement of muscle weakness and muscle fatigue in patients with ALS (Amyotrophic Lateral Sclerosis). The purpose of the study is to assess the effect of tirasemtiv versus placebo on respiratory function but will also evaluate the safety, tolerability and efficacy of tirasemtiv when taken with or without riluzole. Time will be 60 weeks, 16 study visits.
Who may be Eligible
Patients with familial or sporadic ALS diagnosed =24 months prior to screening who are =18 years of age.